Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Foghorn Therapeutics (FHTX) Profit After Tax (2020 - 2025)

Historic Profit After Tax for Foghorn Therapeutics (FHTX) over the last 6 years, with Q3 2025 value amounting to -$15.8 million.

  • Foghorn Therapeutics' Profit After Tax rose 1711.64% to -$15.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$72.1 million, marking a year-over-year increase of 2093.88%. This contributed to the annual value of -$86.6 million for FY2024, which is 1199.48% up from last year.
  • As of Q3 2025, Foghorn Therapeutics' Profit After Tax stood at -$15.8 million, which was up 1711.64% from -$17.9 million recorded in Q2 2025.
  • Over the past 5 years, Foghorn Therapeutics' Profit After Tax peaked at -$14.3 million during Q3 2023, and registered a low of -$30.5 million during Q1 2023.
  • Its 5-year average for Profit After Tax is -$23.6 million, with a median of -$24.1 million in 2023.
  • Its Profit After Tax has fluctuated over the past 5 years, first crashed by 6485.09% in 2021, then surged by 4433.23% in 2023.
  • Foghorn Therapeutics' Profit After Tax (Quarter) stood at -$29.1 million in 2021, then increased by 0.76% to -$28.9 million in 2022, then grew by 16.59% to -$24.1 million in 2023, then rose by 19.09% to -$19.5 million in 2024, then grew by 18.74% to -$15.8 million in 2025.
  • Its Profit After Tax was -$15.8 million in Q3 2025, compared to -$17.9 million in Q2 2025 and -$18.8 million in Q1 2025.